Order Article Reprints

Guida M, Bartolomeo N, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, Minisini AM, Tucci M, Spagnolo F, Occelli M, et al. No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers. 2021; 13(3):475. https://doi.org/10.3390/cancers13030475

Guida, Michele, Nicola Bartolomeo, Pietro Quaglino, Gabriele Madonna, Jacopo Pigozzo, Anna M. Di Giacomo, Alessandro M. Minisini, Marco Tucci, Francesco Spagnolo, Marcella Occelli, and et al. 2021. "No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study" Cancers 13, no. 3: 475. https://doi.org/10.3390/cancers13030475

Guida, M., Bartolomeo, N., Quaglino, P., Madonna, G., Pigozzo, J., Di Giacomo, A. M., Minisini, A. M., Tucci, M., Spagnolo, F., Occelli, M., Ridolfi, L., Queirolo, P., De Risi, I., Quaresmini, D., Gambale, E., Chiaron Sileni, V., Ascierto, P. A., Stigliano, L., Strippoli, S., & on behalf of the Italian Melanoma Intergroup (IMI) Study. (2021). No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers, 13(3), 475. https://doi.org/10.3390/cancers13030475